Literature DB >> 21633538

Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.

Nicolas Williet1, Olivier Dubreuil, Tarek Boussaha, Isabelle Trouilloud, Bruno Landi, Martin Housset, Muriel Botti, Philippe Rougier, Jacques Belghiti, Julien Taieb.   

Abstract

This paper reports the first case of a patient with hepatocellular carcinoma with lymph node metastasis treated by sorafenib combined with gemcitabine plus oxaliplatin, with a partial response and normalization of α fetoprotein, which allowed curative surgery. The potential synergy between these three drugs needs to be confirmed, and is currently being investigated in a randomized phase II trial.

Entities:  

Keywords:  Gemcitabine; Hepatocellular carcinoma; Neoadjuvant therapy; Oxaliplatin; Sorafenib

Mesh：

Substances：

Year:  2011        PMID： 21633538      PMCID： PMC3092880          DOI： 10.3748/wjg.v17.i17.2255

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  23 in total

1.  Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Lawrence S Blaszkowsky; David P Ryan; Jeffrey W Clark; Alona Muzikansky; Kerry Horgan; Susan Sheehan; Kelly E Hale; Peter C Enzinger; Pankaj Bhargava; Keith Stuart
Journal:  J Clin Oncol       Date:  2006-04-20       Impact factor: 44.544

2.  Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

Authors:  Robert S Kerbel
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

3.  [Oxaliplatin neurotoxicity: a report of three cases with post-operative exacerbation].

Authors:  Agnès Cournede; Pauline Ries; Karine Richard; Alexandra Guillain; Laëtitia Dahan; Philippe Grandval; Bertrand Pourroy; Vincent Moutardier; Jean Hardwigsen; Diane Braguer; Jean-François Seitz
Journal:  Gastroenterol Clin Biol       Date:  2005-04

4.  Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.

Authors:  T S Yang; Y C Lin; J S Chen; H M Wang; C H Wang
Journal:  Cancer       Date:  2000-08-15       Impact factor: 6.860

5.  Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach.

Authors:  F Bathaix; D Marion; M Cuinet; E Maillard; F Zoulim; F Mornex; P Merle
Journal:  Gastroenterol Clin Biol       Date:  2010-03-05

Review 6.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

7.  Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

Authors:  S Faivre; E Raymond; J M Woynarowski; E Cvitkovic
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

8.  Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients.

Authors:  Zhao-Chong Zeng; Zhao-You Tang; Jia Fan; Lun-Xiu Qin; Shen-Long Ye; Jian Zhou; Hui-Chuan Sun; Bin-Liang Wang; Jian-Hua Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-15       Impact factor: 7.038

9.  Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.

Authors:  Julien Taïeb; Luminita Bonyhay; Lamia Golli; Michel Ducreux; Emmanuel Boleslawski; Jean-Marie Tigaud; Thierry de Baere; Touraj Mansourbakht; Marie Anna Delgado; Laureut Hannoun; Thierry Poynard; Valerie Boige
Journal:  Cancer       Date:  2003-12-15       Impact factor: 6.860

Review 10.  Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum.

Authors:  Andrew Burroughs; Daniel Hochhauser; Tim Meyer
Journal:  Lancet Oncol       Date:  2004-07       Impact factor: 41.316
View more
  8 in total

Review 1.  Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis.

Authors:  Yu Zhang; Zhi-Long Shi; Xia Yang; Zheng-Feng Yin
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 2.  Progress in systemic therapy of advanced hepatocellular carcinoma.

Authors:  Xin-Lei Gong; Shu-Kui Qin
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 3.  Pediatric hepatocellular carcinoma: challenges and solutions.

Authors:  Irene Schmid; Dietrich von Schweinitz
Journal:  J Hepatocell Carcinoma       Date:  2017-01-16

Review 4.  Neoadjuvant treatment strategies for hepatocellular carcinoma.

Authors:  Lei Xu; Lin Chen; Wei Zhang
Journal:  World J Gastrointest Surg       Date:  2021-12-27

Review 5.  Neoadjuvant Immunotherapy for Hepatocellular Carcinoma.

Authors:  Thomas U Marron; Myron Schwartz; Virginia Corbett; Miriam Merad
Journal:  J Hepatocell Carcinoma       Date:  2022-06-30

Review 6.  Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review.

Authors:  Santhasiri Orrapin; Sasimol Udomruk; Worakitti Lapisatepun; Sutpirat Moonmuang; Areerak Phanphaisarn; Phichayut Phinyo; Dumnoensun Pruksakorn; Parunya Chaiyawat
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

7.  Inferior vena cava tumor thrombus that directly infiltrated from paracaval lymph node metastases in a patient with recurrent hepatocellular carcinoma.

Authors:  Shinya Imada; Kohei Ishiyama; Kentaro Ide; Tsuyoshi Kobayashi; Hironobu Amano; Hirotaka Tashiro; Koji Arihiro; Hiroshi Aikata; Kazuaki Chayama; Hideki Ohdan
Journal:  World J Surg Oncol       Date:  2013-08-06       Impact factor: 2.754

8.  Resection of "down-staged" advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report.

Authors:  Zhenyu Hou; Keyun Zhu; Xuejiao Yang; Hongyuan Zhou; Ping Chen; Ge Yu; Xiaolin Zhu; Yunlong Cui; Tianqiang Song; Qiang Li; Huikai Li; Ti Zhang
Journal:  Transl Cancer Res       Date:  2020-08       Impact factor: 1.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.